Ultralife (ULBI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Trade with 70% Backtested Accuracy
Analyst Views on ULBI
About ULBI
About the author
Ultralife Corporation Expands Leadership Team to Accelerate Growth Initiatives
Leadership Changes: Ultralife Corporation (NASDAQ: ULBI) has appointed Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President of Sales & Business Development, effective January 6, 2025.
Roles and Responsibilities: Luke will focus on corporate strategy and global operations, while Pope will drive market growth and revenue through strategic alliances, leveraging their extensive industry experience.
Company Overview: Ultralife Corporation provides power, communications, and electronic systems to commercial, military, and government clients worldwide, positioning itself among the best manganese stocks.
Investment Perspective: While ULBI is recognized as a potential investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk.
Ultralife (ULBI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Ultralife Corporation to Report Second Quarter Results on August 7, 2025
Ultralife Corporation Q2 Results Announcement: Ultralife Corporation will report its second quarter results on August 7, 2025, before the market opens, followed by an investor conference call and webcast at Noon ET.
Participation Details for Investors: Participants wishing to join the conference call by phone must pre-register to receive dial-in information and a personal identification number, with a live webcast also available on the company's website.
Ultralife outlines Q2 Electrochem integration and strategic growth initiatives
Financial Performance: Ultralife Corporation reported Q1 2025 sales of $50.7 million with a net income of $1.9 million, reflecting strong government-defense sales and the full contribution from the Electrochem acquisition, despite challenges such as tariff impacts and declining medical battery sales.
Outlook and Challenges: Management expressed confidence in future growth driven by operational improvements and new product lines, while acknowledging risks related to tariffs, delayed shipments, and macroeconomic uncertainties affecting revenue predictability.
Ultralife Non-GAAP EPS of $0.13 misses by $0.02, revenue of $50.7M beats by $2.7M
Earnings Performance: Ultralife Corporation reported a Q1 Non-GAAP EPS of $0.13, missing expectations by $0.02, while revenue increased by 21% year-over-year to $50.7 million, surpassing estimates by $2.7 million.
Backlog and Adjusted EBITDA: The company's adjusted EBITDA rose slightly to $5.4 million compared to the previous year's first quarter, with a backlog of high-confidence orders totaling $95.0 million, down from $102.2 million at the end of Q4 2024.
Ultralife Corporation Reports Fourth Quarter Results
Fourth Quarter Financial Results: Ultralife Corporation reported a slight decline in sales to $43.9 million for Q4 2024, with notable increases in Battery & Energy Products but significant decreases in Communications Systems. The company faced one-time costs related to the acquisition of Electrochem Solutions, resulting in lower operating income and GAAP EPS compared to the previous year.
Acquisition Integration and Future Outlook: Following the acquisition of Electrochem, Ultralife has begun integrating the new entity to enhance operational efficiencies and leverage growth opportunities in high-demand markets. The company expressed confidence in achieving profitable growth and reducing debt as it enters 2025 with a strong backlog of orders.
Ultralife Corporation Expands Leadership Team to Accelerate Growth Initiatives
Leadership Changes: Ultralife Corporation (NASDAQ: ULBI) has appointed Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President of Sales & Business Development, effective January 6, 2025.
Roles and Responsibilities: Luke will focus on corporate strategy and global operations, while Pope will drive market growth and revenue through strategic alliances, leveraging their extensive industry experience.
Company Overview: Ultralife Corporation provides power, communications, and electronic systems to commercial, military, and government clients worldwide, positioning itself among the best manganese stocks.
Investment Perspective: While ULBI is recognized as a potential investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk.
Ultralife (ULBI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Ultralife Corporation to Report Second Quarter Results on August 7, 2025
Ultralife Corporation Q2 Results Announcement: Ultralife Corporation will report its second quarter results on August 7, 2025, before the market opens, followed by an investor conference call and webcast at Noon ET.
Participation Details for Investors: Participants wishing to join the conference call by phone must pre-register to receive dial-in information and a personal identification number, with a live webcast also available on the company's website.
Ultralife outlines Q2 Electrochem integration and strategic growth initiatives
Financial Performance: Ultralife Corporation reported Q1 2025 sales of $50.7 million with a net income of $1.9 million, reflecting strong government-defense sales and the full contribution from the Electrochem acquisition, despite challenges such as tariff impacts and declining medical battery sales.
Outlook and Challenges: Management expressed confidence in future growth driven by operational improvements and new product lines, while acknowledging risks related to tariffs, delayed shipments, and macroeconomic uncertainties affecting revenue predictability.
Ultralife Non-GAAP EPS of $0.13 misses by $0.02, revenue of $50.7M beats by $2.7M
Earnings Performance: Ultralife Corporation reported a Q1 Non-GAAP EPS of $0.13, missing expectations by $0.02, while revenue increased by 21% year-over-year to $50.7 million, surpassing estimates by $2.7 million.
Backlog and Adjusted EBITDA: The company's adjusted EBITDA rose slightly to $5.4 million compared to the previous year's first quarter, with a backlog of high-confidence orders totaling $95.0 million, down from $102.2 million at the end of Q4 2024.
Ultralife Corporation Reports Fourth Quarter Results
Fourth Quarter Financial Results: Ultralife Corporation reported a slight decline in sales to $43.9 million for Q4 2024, with notable increases in Battery & Energy Products but significant decreases in Communications Systems. The company faced one-time costs related to the acquisition of Electrochem Solutions, resulting in lower operating income and GAAP EPS compared to the previous year.
Acquisition Integration and Future Outlook: Following the acquisition of Electrochem, Ultralife has begun integrating the new entity to enhance operational efficiencies and leverage growth opportunities in high-demand markets. The company expressed confidence in achieving profitable growth and reducing debt as it enters 2025 with a strong backlog of orders.
